Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design

[1]  Andrew S. Mugglin,et al.  Transcatheter Aortic‐Valve Replacement with a Self‐Expanding Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[2]  S. Pocock,et al.  Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial , 2018, The Lancet.

[3]  Neil Chapman,et al.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial , 2017, The Lancet.

[4]  A. Kastrati,et al.  Drug-eluting stents versus bare metal stents for the prevention of restenosis in patients with renovascular disease. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  G. Chatellier,et al.  Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future , 2017, European heart journal.

[6]  Adam Himes,et al.  Incorporation of stochastic engineering models as prior information in Bayesian medical device trials , 2017, Journal of biopharmaceutical statistics.

[7]  Andrew S. Mugglin,et al.  Surgical or Transcatheter Aortic‐Valve Replacement in Intermediate‐Risk Patients , 2017, The New England journal of medicine.

[8]  S. Pocock,et al.  The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. , 2016, American heart journal.

[9]  G. Chatellier,et al.  Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. , 2015, European heart journal.

[10]  Deepak L. Bhatt,et al.  Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. , 2015, European heart journal.

[11]  Steven D. Hochman,et al.  Revascularization versus Medical Therapy for Renal Artery Stenosis , 2015 .

[12]  Deepak L. Bhatt,et al.  Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.

[13]  Michael Böhm,et al.  Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study , 2014, The Lancet.

[14]  Fang Chen,et al.  Use of historical control data for assessing treatment effects in clinical trials , 2014, Pharmaceutical statistics.

[15]  Ralph B D'Agostino,et al.  Stenting and medical therapy for atherosclerotic renal-artery stenosis. , 2014, The New England journal of medicine.

[16]  R. Bersin,et al.  Nine‐month results of the REFORM study , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[17]  M. Jaff,et al.  Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: results from the HERCULES trial. , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[18]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[19]  John K Kruschke,et al.  Bayesian data analysis. , 2010, Wiley interdisciplinary reviews. Cognitive science.

[20]  C. O'shaughnessy,et al.  Safety and efficacy of renal artery stenting following suboptimal renal angioplasty for de novo and restenotic ostial lesions: results from a nonrandomized, prospective multicenter registry. , 2010, Journal of vascular and interventional radiology : JVIR.

[21]  W. Mali,et al.  Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. , 2009, Annals of internal medicine.

[22]  C. Baigent,et al.  Revascularization versus medical therapy for renal-artery stenosis. , 2009, The New England journal of medicine.

[23]  M. Jaff,et al.  Evaluation of the safety and effectiveness of renal artery stenting after unsuccessful balloon angioplasty: the ASPIRE-2 study. , 2005, Journal of the American College of Cardiology.

[24]  D. Berry.  Bayesian Statistics and the Efficiency and Ethics of Clinical Trials , 2004 .

[25]  P. Krijnen,et al.  The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. , 2000, The New England journal of medicine.

[26]  J. Ibrahim,et al.  Power prior distributions for regression models , 2000 .